| The cell-cycle regulator CDK4: an emerging therapeutic target in melanoma KE Sheppard, GA McArthur Clinical Cancer Research 19 (19), 5320-5328, 2013 | 300 | 2013 |
| Response of BRAF-Mutant Melanoma to BRAF Inhibition Is Mediated by a Network of Transcriptional Regulators of Glycolysis TJ Parmenter, M Kleinschmidt, KM Kinross, ST Bond, J Li, MR Kaadige, ... Cancer discovery 4 (4), 423-433, 2014 | 290 | 2014 |
| Targeting PI3 kinase/AKT/mTOR signaling in cancer K Sheppard, KM Kinross, B Solomon, RB Pearson, WA Phillips Critical Reviews™ in Oncogenesis 17 (1), 2012 | 284 | 2012 |
| Deregulation of MYCN, LIN28B and LET7 in a Molecular Subtype of Aggressive High-Grade Serous Ovarian Cancers Å Helland, MS Anglesio, J George, PA Cowin, CN Johnstone, CM House, ... PloS one 6 (4), e18064, 2011 | 218 | 2011 |
| An activating Pik3ca mutation coupled with Pten loss is sufficient to initiate ovarian tumorigenesis in mice KM Kinross, KG Montgomery, M Kleinschmidt, P Waring, I Ivetac, A Tikoo, ... The Journal of clinical investigation 122 (2), 553-557, 2012 | 214 | 2012 |
| Loss of CDKN2A expression is a frequent event in primary invasive melanoma and correlates with sensitivity to the CDK4/6 inhibitor PD0332991 in melanoma cell … RJ Young, K Waldeck, C Martin, JH Foo, DP Cameron, L Kirby, H Do, ... Pigment cell & melanoma research 27 (4), 590-600, 2014 | 204 | 2014 |
| Second AKT: the rise of SGK in cancer signalling MA Bruhn, RB Pearson, RD Hannan, KE Sheppard Growth factors 28 (6), 394-408, 2010 | 183 | 2010 |
| Adrenocortical steroids and the brain JW Funder, K Sheppard Annual review of Physiology 49 (1), 397-411, 1987 | 179 | 1987 |
| The type I and type II 11β-hydroxysteroid dehydrogenase enzymes Z Krozowski, KXZ Li, K Koyama, RE Smith, VR Obeyesekere, ... The Journal of steroid biochemistry and molecular biology 69 (1-6), 391-401, 1999 | 177 | 1999 |
| AKT promotes rRNA synthesis and cooperates with c-MYC to stimulate ribosome biogenesis in cancer JC Chan, KM Hannan, K Riddell, PY Ng, A Peck, RS Lee, S Hung, ... Science signaling 4 (188), ra56-ra56, 2011 | 168 | 2011 |
| First-in-human RNA polymerase I transcription inhibitor CX-5461 in patients with advanced hematologic cancers: results of a phase I dose-escalation study A Khot, N Brajanovski, DP Cameron, N Hein, KH Maclachlan, E Sanij, ... Cancer discovery 9 (8), 1036-1049, 2019 | 163 | 2019 |
| The transcription cofactor c-JUN mediates phenotype switching and BRAF inhibitor resistance in melanoma R Ramsdale, RN Jorissen, FZ Li, S Al-Obaidi, T Ward, KE Sheppard, ... Science signaling 8 (390), ra82-ra82, 2015 | 135 | 2015 |
| AKT-independent PI3-K signaling in cancer–emerging role for SGK3 MA Bruhn, RB Pearson, RD Hannan, KE Sheppard Cancer management and research, 281-292, 2013 | 127 | 2013 |
| Regression of pressure overload-induced left ventricular hypertrophy in mice XM Gao, H Kiriazis, XL Moore, XH Feng, K Sheppard, A Dart, XJ Du American Journal of Physiology-Heart and Circulatory Physiology 288 (6 …, 2005 | 123 | 2005 |
| CX-5461 activates the DNA damage response and demonstrates therapeutic efficacy in high-grade serous ovarian cancer E Sanij, KM Hannan, J Xuan, S Yan, JE Ahern, AS Trigos, N Brajanovski, ... Nature communications 11 (1), 2641, 2020 | 112 | 2020 |
| LRP1B deletion in high-grade serous ovarian cancers is associated with acquired chemotherapy resistance to liposomal doxorubicin PA Cowin, J George, S Fereday, E Loehrer, P Van Loo, C Cullinane, ... Cancer research 72 (16), 4060-4073, 2012 | 111 | 2012 |
| Inhibition of RNA polymerase I transcription initiation by CX-5461 activates non-canonical ATM/ATR signaling J Quin, KT Chan, JR Devlin, DP Cameron, J Diesch, C Cullinane, J Ahern, ... Oncotarget 7 (31), 49800, 2016 | 104 | 2016 |
| Synergistic inhibition of ovarian cancer cell growth by combining selective PI3K/mTOR and RAS/ERK pathway inhibitors KE Sheppard, C Cullinane, KM Hannan, M Wall, J Chan, F Barber, J Foo, ... European journal of cancer 49 (18), 3936-3944, 2013 | 96 | 2013 |
| 11β-Hydroxysteroid dehydrogenase 1 transforms 11-dehydrocorticosterone into transcriptionally active glucocorticoid in neonatal rat heart KE Sheppard, DJ Autelitano Endocrinology 143 (1), 198-204, 2002 | 96 | 2002 |
| Mineralocorticoid specificity of renal type I receptors: in vivo binding studies K Sheppard, JW Funder American Journal of Physiology-Endocrinology and Metabolism 252 (2), E224-E229, 1987 | 90 | 1987 |
